Docoh
Loading...

FGEN FibroGen

News

Pro users get this 30m faster
FibroGen Receives Rare Pediatric Disease Designation From The FDA For Pamrevlumab For Treatment Of Duchenne Muscular Dystrophy
15 Apr 21
Biotech, News, FDA, General
FibroGen, Inc. (NASDAQ:FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company's anti-CTGF antibody, pamrevlumab, for the treatment of
FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
12 Apr 21
News, FDA
FibroGen, Inc. (NASDAQ:FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company's anti-CTGF antibody, pamrevlumab, for the treatment of patients with
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
10 Apr 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of defensives such as healthcare stocks.
Stocks That Hit 52-Week Lows On Friday
9 Apr 21
News, Intraday Update, Markets, Movers, Trading Ideas
On Friday morning, 13 companies achieved new lows for the year.
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
9 Apr 21
Biotech, News, Penny Stocks, Small Cap, FDA, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8)
Stocks That Hit 52-Week Lows On Thursday
8 Apr 21
News, Intraday Update, Markets, Movers, Trading Ideas
On Thursday morning, 6 companies achieved new lows for the year.
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
8 Apr 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7)
36 Biggest Movers From Yesterday
8 Apr 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers UTime Limited (NASDAQ: UTME) shares jumped 110.7% to close at $82.17 on Wednesday. UTime shares jumped 875% on Tuesday after the company priced its IPO at $4 per share.
Mid-Afternoon Market Update: Dow Falls 25 Points; Homology Medicines Shares Slide
7 Apr 21
Earnings, News, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Wednesday, the Dow traded down 0.08% to 33,404.98 while the NASDAQ rose 0.02% to 13,701.64. The S&P also rose, gaining 0.09% to 4,077.69.
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 Apr 21
Intraday Update, Markets, Movers
Mid-Day Market Update: Crude Oil Down Over 1%; FibroGen Shares Plummet
7 Apr 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Wednesday, the Dow traded up 0.02% to 33,437.41 while the NASDAQ rose 0.23% to 13,729.29. The S&P also rose, gaining 0.16% to 4,080.61.
28 Stocks Moving In Wednesday's Mid-Day Session
7 Apr 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers UTime Limited (NASDAQ: UTME) jumped 97.4% to $76.99. UTime shares jumped 875% on Tuesday after the company priced its IPO at $4 per share.
Stocks That Hit 52-Week Lows On Wednesday
7 Apr 21
News, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's morning session, 5 stocks hit new 52-week lows.
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2021
7 Apr 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Why FibroGen's Stock is Down During Today's Session
7 Apr 21
Movers, Trading Ideas
FibroGen's Stock Price And Volume Action FibroGen's (NASDAQ:FGEN) stock has been falling Wednesday, down 35.34% to a price of $22.25. The stock's volume is currently 2.35 million, which is roughly 176.48% of its recent 30-day volume average of 1.33 million.
Mid-Morning Market Update: Markets Mostly Higher; RPM Earnings Beat Views
7 Apr 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Wednesday, the Dow traded up 0.16% to 33,483.20 while the NASDAQ fell 0.05% to 13,692.06. The S&P also rose, gaining 0.12% to 4,078.93.
10 Biggest Price Target Changes For Wednesday
7 Apr 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Keybanc raised Applied Materials, Inc. (NASDAQ: AMAT) price target from $144 to $151. Applied Materials shares rose 0.1% to $139.65 in pre-market trading.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 Apr 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award
7 Apr 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, Top Stories, Pre-Market Outlook
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 6)
Mizuho Downgrades FibroGen to Neutral, Announces $29 Price Target
7 Apr 21
News, Downgrades, Price Target, Analyst Ratings
Mizuho analyst Difei Yang downgrades FibroGen (NASDAQ:FGEN) from Buy to Neutral and announces $29 price target.

Press releases

Pro users get this 30m faster
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
16 Apr 21
Press Releases
Los Angeles, California--(Newsfile Corp. - April 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - FGEN
16 Apr 21
Press Releases
Radnor, Pennsylvania--(Newsfile Corp. - April 16, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
16 Apr 21
Press Releases
New York, New York--(Newsfile Corp. - April 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc.
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN
15 Apr 21
Press Releases
New Orleans, Louisiana--(Newsfile Corp. - April 15, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11,
FGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against FibroGen Inc.
15 Apr 21
Small Cap, Press Releases
Glancy Prongay & Murray LL
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
15 Apr 21
Press Releases
New York, New York--(Newsfile Corp. - April 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ:FGEN) alleging that the Company
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
15 Apr 21
Press Releases
New York, New York--(Newsfile Corp. - April 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc.
Portnoy Law: Lawsuit Filed On Behalf of FibroGen, Inc. Investors
15 Apr 21
News, Legal, Press Releases
Click here to join the case LOS ANGELES, April 15, 2021 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of FibroGen, Inc. ("FibroGen" or
SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders
15 Apr 21
Press Releases
Shareholder rights law firm Robbins LLP announces that a purchaser of FibroGen, Inc. (NASDAQ:FGEN) filed a class action complaint against the Company and its officers and directors for alleged violations of the
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
15 Apr 21
Press Releases
LOS ANGELES, April 15, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
15 Apr 21
Press Releases
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen,
FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
15 Apr 21
Press Releases
NEW YORK, April 15, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
15 Apr 21
News, Legal, Press Releases
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
15 Apr 21
Health Care, Press Releases
SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company's anti-CTGF
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ebang, 3D Systems, Amdocs, and FibroGen and Encourages Investors to Contact the Firm
14 Apr 21
News, Legal, Press Releases
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of
FGEN INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Fibrogen Inc.
14 Apr 21
News, Legal, Press Releases
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or
FibroGen Investor Alert
14 Apr 21
Press Releases
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 14,
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
14 Apr 21
Press Releases
New York, New York--(Newsfile Corp. - April 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ:FGEN) alleging that the Company
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
14 Apr 21
Small Cap, Press Releases
Shareholders with $100,000 losses or more are encouraged to contact the firm
FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
14 Apr 21
Press Releases
RADNOR, Pa., April 14, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the